PILA PHARMA AB is a private, Swedish “micro-pharma” aiming at developing innovative new approaches to treat diabetes. PILA PHARMA owns issued use-patents that give the exclusive right to treat diabetes and obesity with antagonists of the TRPV1 receptor. The company has recently acquired the TRPV1 antagonist asset previously owned by Ario Pharma Ltd (Cambridge, U.K.).

This asset includes a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data.

The TRPV1 target (also called the “chili-receptor”) has been shown to have applications across pain and inflammatory diseases and is speculated to have a role in diabetes as well.

PILA PHARMA AB is dedicated to bringing the TRPV1 antagonist, a truly innovative oral anti-diabetes product closer to the market. And in addition to our current research collaborations, we intend to finance the development of our pre-clinical candidate through partnering, venture capital, corporate funds and/or grants.


PILA PHARMA yesterday won the title ‘Best pitch 2016’ at the ALMI Invest Seed Day in Stockholm, Sweden !
The competition was held amongst 18 selected out of ALMI Invests portfolio companies.
Nextbig 2016 3
Nextbig 2016 3
Nextbig 2016 2
Nextbig 2016 5
Nextbig 2016 4
Nextbig 2016 6

At BioEurope Spring in Stockholm in April 2016 Dr. Dorte Gram, CEO of PILA Pharma was interviewed by the organizers about the current status and our plans going forward.

Please find the links below:


We are proud to be on the cover of the September 2016 issue of Nordic Life Science Magazine as representatives of Nordic Life Science companies.

Read the article here
Read the magazine here